凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06821 凯莱英

未开盘 08-13 16:08:14

119.800

-6.400

-5.07%

最高127.100	最低119.000	成交量184.99万
今开126.200	昨收126.200	日振幅6.42%
总市值432.48亿	流通市值33.01亿	总股本3.61亿
成交额2.27亿	换手率6.71%	流通股本2,755万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06821","market":"HK","secType":"STK","nameCN":"凯莱英","latestPrice":119.8,"timestamp":1786608494006,"preClose":126.2,"halted":0,"volume":1849912,"delay":0,"changeRate":-0.05071315372424727,"floatShares":27553260,"shares":361000000,"eps":3.6764461882528354,"marketStatus":"未开盘","change":-6.4,"latestTime":"08-13 16:08:14","open":126.2,"high":127.1,"low":119,"amount":226520643,"amplitude":0.064184,"askPrice":120,"askSize":300,"bidPrice":119.8,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":3.61592443802723,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786671000000},"marketStatusCode":0,"adr":0,"listingDate":1639065600000,"exchange":"SEHK","adjPreClose":126.2,"dividendRate":0.012626,"openAndCloseTimeList":[[1786584600000,1786593600000],[1786597200000,1786608000000]],"volumeRatio":1.205993,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":173.81,"timestamp":1786604400000,"preClose":175,"halted":0,"volume":17410800,"delay":0,"premium":"-40.76"}},"requestUrl":"/m/hq/s/06821","defaultTab":"news","newsList":[{"id":"2659594311","title":"JPMorgan Chase & Co.减持凯莱英(06821.HK)14.5767万股 每股作价约121.64港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659594311","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659594311?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:03","pubTimestamp":1786619017,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169267159","title":"凯莱英：摩根大通减持，好仓比例降至8.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169267159","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169267159?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:12","pubTimestamp":1786612351,"startTime":"0","endTime":"0","summary":"摩根大通于2026年8月10日以每股均价121.6438港元卖出凯莱英14.58万股，涉资约1773.17万港元。同时，摩根大通的淡仓因股本衍生工具到期注销，持股量由97.45万股降至69.21万股，淡仓比例由3.5%降至2.48%。摩根大通此次减持前持有凯莱英好仓254.62万股，占比9.14%；减持后持股量为240.05万股，好仓比例降至8.62%。淡仓方面，减持前持有97.45万股，占比3.5%；减持后持有69.21万股，占比2.48%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125318913","title":"异动解读｜凯莱英盘中下跌5.15%，子公司亏损数据披露叠加多家机构持续减持","url":"https://stock-news.laohu8.com/highlight/detail?id=1125318913","media":"行情直击","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125318913?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:14","pubTimestamp":1786605251,"startTime":"0","endTime":"0","summary":"8月13日，凯莱英盘中下跌5.15%，报119.7港元，成交额1.95亿港元。消息面上，公司8月12日披露全资子公司上海凯莱英经审计财务数据，该子公司2025年度净亏损0.44亿元，截至2025年末流动负债高于流动资产0.84亿元，未分配亏损达4.26亿元。同时，近期南方基金、Norges Bank、Schroders PLC等多家机构先后减持公司H股。此前凯莱英A股8月7日涨停、H股8月11日涨超5%后积累较大获利盘，短期回调压力显现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903920","title":"凯莱英（002821）披露2026年A股限制性股票激励计划激励名单审核意见及公示情况的说明，8月12日股价下跌0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903920","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658903920?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:05","pubTimestamp":1786543517,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，凯莱英报收于175.0元，较前一交易日下跌0.36%，最新总市值为631.37亿元。该股当日开盘175.47元，最高179.1元，最低173.88元，成交额达19.55亿元，换手率为3.5%。公告显示，公司董事会薪酬与考核委员会对2026年A股限制性股票激励计划拟激励对象的姓名及职务进行了公示，公示时间为2026年7月9日至7月19日，通过公司内网公示，期间未收到任何异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200039934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06821","159982","LU1328615791.USD","BK0239","002821","BK1191","BK0132","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176444956","title":"凯莱英(06821)披露上海子公司财务：2025年收入4.70亿元 首季录得1.40亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176444956","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176444956?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:06","pubTimestamp":1786536398,"startTime":"0","endTime":"0","summary":"凯莱英医药集团（天津）股份有限公司8月12日在港交所发布海外监管公告，披露其全资子公司上海凯莱英生物技术发展有限公司经安永华明会计师事务所审计的2025年度及2026年一季度财务数据。上海凯莱英2025年度实现营业收入4.70亿元，主营业务贡献收入4.42亿元；全年实现净亏损0.44亿元。截至2025年12月31日，上海凯莱英流动负债高于流动资产0.84亿元；年末未分配亏损4.26亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123539877","title":"凯莱英发布2026年A股限制性股票激励计划激励名单审核结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1123539877","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123539877?lang=zh_cn&edition=full","pubTime":"2026-08-12 19:56","pubTimestamp":1786535798,"startTime":"0","endTime":"0","summary":"2026年8月12日，凯莱英医药集团（天津）股份有限公司在香港联合交易所刊发海外监管公告，披露其董事会薪酬与考核委员会对《2026年A股限制性股票激励计划》拟激励对象名单的审核意见及公示情况。公告显示，公司已于2026年7月8日召开第五届董事会第十一次会议，审议并通过《关于公司〈2026年A股限制性股票激励计划（草案）〉及其摘要的议案》等相关事项，并于巨潮资讯网对外披露。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170710686","title":"凯莱英（06821）完成限制性股票激励计划内幕交易自查 未发现违规","url":"https://stock-news.laohu8.com/highlight/detail?id=1170710686","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170710686?lang=zh_cn&edition=full","pubTime":"2026-08-12 19:51","pubTimestamp":1786535509,"startTime":"0","endTime":"0","summary":"凯莱英医药集团（天津）股份有限公司8月13日在港交所披露海外监管公告称，公司已就其《2026年A股限制性股票激励计划（草案）》完成内幕信息知情人及激励对象自查，未发现利用内幕信息买卖公司股票的情形，所有激励对象均符合相关监管规定。公告显示，公司于2026年7月8日召开第五届董事会第十一次会议，通过激励计划草案及其摘要等相关议案，并随后在巨潮资讯网予以披露。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152248005","title":"凯莱英（06821）将于8月24日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1152248005","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152248005?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:36","pubTimestamp":1786523813,"startTime":"0","endTime":"0","summary":"凯莱英医药集团（天津）股份有限公司（06821）8月12日公告称，公司董事会会议拟于2026年8月24日（星期一）召开，议程之一为审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜。\n公告显示，董事会目前由9名成员组成，包括董事长、执行董事兼首席执行官Hao Hong博士，执行董事杨蕊女士、张达先生及洪亮先生，非执行董事Ye Song博士及张婷女士，以及独立非执行董事孙雪娇博士、侯欣一博士和谢维恺先生。\n公司未在本次公告中披露任何财务数据或业绩指标。待董事会审议通过后，凯莱英将对外发布2026年上半年业绩报告，相关数据以届时公告内容为准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969219","title":"港股午评|恒生指数早盘跌0.63%    CRO概念继续走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969219?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:00","pubTimestamp":1786420834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.63%，跌163点，报25773点；恒生科技指数跌1.27%。港股早盘成交1158亿港元。药明康德司法取得进展，有利于CXO公司在海外争取新的订单。再鼎医药涨超5%，Q2产品收入环比增长11%，花旗看好中国业务下半年企稳。津上机床中国涨超5%，电子与AI液冷两大领域在新订单占比约四成。黄金股普遍承压。油价走高加剧通胀上行担忧，美联储鹰派释放强硬信号。中国黄金国际跌2.5%；紫金矿业跌3.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1242518931.SGD","LU0737861772.HKD","LU0348767384.USD","02833","BK1190","06951","LU1808992512.USD","PONY","LU1720050803.USD","LU0456854461.SGD","LU2039709279.SGD","LU2097828474.EUR","09067","03032","LU0327786744.USD","BK1191","688234","LU0165289439.USD","LU0918141705.HKD","LU1504937902.USD","LU0149721374.USD","LU0561508036.HKD","ZLAB","LU0868486357.SGD","LU0370786039.SGD","HSI","LU0634319403.HKD","07300","LU0043850808.USD","LU0082770016.USD","BK1576","LU0307460666.USD","LU0588546209.SGD","LU0828238088.HKD","LU0871576103.HKD","HK0000306701.USD","LU0287142896.SGD","LU1769817096.USD","LU2097828557.USD","LU0061477393.USD","LU0173614495.USD","LU1481107354.HKD","02026","03417","LU0106252389.USD","01651","LU0211977185.USD","LU0348825331.USD","SG9999003461.SGD","688062","LU0140636845.USD","LU0540923850.HKD","BK1583","03037","LU0329678337.USD","06616","513600","LU1988902786.USD","BK1198","BK1161","BK1141","LU1188198961.HKD","ZIJMY","LU0326950275.SGD","BK1129","09688","LU1303224171.USD","BK1587","LU0048580855.USD","SG9999002463.SGD","83115","03088","HK0000306685.HKD","02899","LU1794554557.SGD","03033","01541","LU0244354667.USD","LU0431992006.USD","LU2488822045.USD","03423","BK1544","LU0417516738.SGD","LU0737861699.HKD","LU1961090484.USD","BK1592","01548","02837","07500","LU0164880469.USD","LU0417516902.SGD","300408","LU2097828714.EUR","06821","HK0000320223.HKD","SG9999004220.SGD","03759","LU0328353924.USD","LU0266512127.USD","BK1505","LU1105468828.SGD","LU2264538146.SGD","LU0049853897.USD","LU0918141887.USD","LU0345780521.USD","LU2460026573.USD","LU0828237940.HKD","LU0345780281.USD","LU0531971595.HKD","LU0348735423.USD","07200","LU1251922891.USD","02631","LU0329678170.USD","LU1064131342.USD","LU0082770016.SGD","BK1169","SG9999001093.SGD","JINFF","LU0979878070.USD","LU1282648689.USD","LU0181495838.USD","LU3063872942.SGD","HSTECH","IE0032431581.USD","LU0266512473.USD","LU2399975544.HKD","LU0886674414.USD","LU1224709979.USD","LU2177674079.SGD","LU0164865239.USD","LU0572944931.SGD","LU0096374516.USD","02800","HHImain","09088","601899","BK1594","BK1170","002821","LU0274383008.USD","LU0348814723.USD","BK1574","LU2097828631.EUR","BK1588","03067","LU0269904917.USD","82800","LU0469268626.HKD","LU0463099449.HKD","MCHmain","LU1770034418.SGD","LU0620787316.HKD","LU0348816934.USD","LU0348766576.USD","03115","LU0828237510.HKD","BK1183","LU0797268264.HKD","09115","LU0228659784.USD","LU0039217434.USD","LU1769817179.HKD","03419","LU2226246903.HKD","LU0278937759.USD","02493","300759","LU1242518857.USD","LU1719994722.HKD","02099","07226","LU0106959298.USD","LU1831875114.USD","LU2097828805.USD","LU1048596156.SGD","LU0348827113.USD","LU0821914370.USD","LU0164939612.USD","LU2008162690.USD","HK0000320264.USD","BK1109","LU0509642566.USD","07552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194920646","title":"异动解读｜凯莱英盘中上涨5.07%，CXO板块持续受药明康德中报利好提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1194920646","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194920646?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:05","pubTimestamp":1786417543,"startTime":"0","endTime":"0","summary":"8月11日，凯莱英盘中上涨5.07%，报130.6港元，成交额7276.73万港元。消息面上，CXO板块龙头药明康德此前披露中报，上半年营收288.97亿元同比增长38.93%，扣非净利润同比增长89.39%并上调全年业绩指引，持续提振医药外包概念股。凯莱英A股8月7日已涨停，H股延续补涨态势。此外，公司近期公告联合高瓴祈睿等向子公司凯莱英BIO合计增资12.4亿元，用于大分子CDMO产能建设，基本面支撑明确。同时公司拟采纳H股限制性股票计划，将于8月20日召开临时股东大会审议。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950072","title":"凯莱英遭南方基金减持22.8万股 每股作价约109.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950072","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950072?lang=zh_cn&edition=full","pubTime":"2026-08-11 08:00","pubTimestamp":1786406400,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，8月6日，南方基金减持凯莱英（06821）22.8万股，每股作价109.6099港元，总金额约为2499.11万港元。减持后最新持股数目为119.64万股，最新持股比例为4.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-08-11/doc-inimwyqt7616761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","002821","06821","LU1328615791.USD","EWH","BK1191","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658393390","title":"南方基金减持凯莱英(06821.HK)22.8万股 每股作价约109.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658393390","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658393390?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:22","pubTimestamp":1786360976,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06821","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658609113","title":"医药外包概念股集体扬升 药明生物（02269）涨4.36% 机构指行业景气度上行信号明确","url":"https://stock-news.laohu8.com/highlight/detail?id=2658609113","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658609113?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:58","pubTimestamp":1786327110,"startTime":"0","endTime":"0","summary":"消息面上，国金证券发布研报指，CXO行业已完整经历一轮产业周期，当下行业景气度上行信号明确。目前，随着外部压力缓释、全球投融资回暖，国内BD持续升温，行业已进入内外需共振、新分子赛道放量、订单与业绩逐季改善的新一轮复苏上行周期。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987777","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127","BK1141","HK0000320264.USD","KURE","LU0307460666.USD","01521","LU0348767384.USD","LU0320764599.SGD","BK1515","LU0043850808.USD","LU0417516738.SGD","LU0819121731.USD","02269","09939","BK1574","LU0052750758.USD","01548","LU0140636845.USD","06821","IE00B0JY6N72.USD","LU0588546209.SGD","LU1880383366.USD","BK1521","LU0051755006.USD","LU3063872942.SGD","159938","LU2242644610.SGD","LU0516422366.SGD","BK1589","LU0456827905.SGD","LU2125910500.SGD","BK1161","LU0979878070.USD","LU1242518857.USD","SG9999002562.SGD","01873","LU1046422090.SGD","LU0823426308.USD","HK0000306701.USD","LU0181495838.USD","BK1191","LU0516423174.USD","LU0823426480.USD","LU2039709279.SGD","LU1720050803.USD","LU1242518931.SGD","LU0572944931.SGD","BK1576","02359","LU0708995583.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657061918","title":"千亿研发订单共振，CRO板块集体涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2657061918","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657061918?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:10","pubTimestamp":1786093801,"startTime":"0","endTime":"0","summary":"8月7日，A股CRO板块上演“全员狂欢”。多重逻辑共振整体看来，本轮CRO行情是产业基本面、全球需求、企业业绩、政策技术四大逻辑共同验证的结果。从初创Biotech到千亿市值跨国药企，超七成研发环节选择外包，CRO深度嵌入药企研发全周期。从产业逻辑来看，当日集体大涨源于全球新药研发需求回暖，国内CRO企业成本优势凸显，海外订单回流预期升温。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/07/20260807386936.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/07/20260807386936.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260807/32329029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["MEDX","BK1191","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657970076","title":"A股收评：沪指涨1.02%，超2800股上涨！CRO概念、AI硬件板块爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2657970076","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657970076?lang=zh_cn&edition=full","pubTime":"2026-08-07 15:03","pubTimestamp":1786086238,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0880133367.SGD","BK0209","LU1993786604.SGD","06821","000001","BK0183","LU0067412154.USD","LU1807302812.USD","LU0501845795.SGD","603233","LU1655091616.SGD","BK0239","LU0072913022.USD","BK0028","BK0185","BK0012","BK0114","BK0278","BK0132","LU1580142542.USD","IE00B0JY6N72.USD","LU1226287529.USD","LU1328615791.USD","BK0187","LU1781817850.SGD","BK0201","BK0188","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148516721","title":"异动解读｜凯莱英盘中上涨6.23%，CXO板块延续药明康德中报利好提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1148516721","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148516721?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:20","pubTimestamp":1786069206,"startTime":"0","endTime":"0","summary":"8月7日，凯莱英盘中上涨6.23%，报115.9港元，成交额6047.7万港元。消息面上，CXO板块龙头药明康德此前披露中报，上半年营收288.97亿元同比增长38.93%，扣非净利润同比增长89.39%，并全面上调全年业绩指引，持续提振医药外包概念股。凯莱英8月4日受此利好大涨近8%后，8月6日因机构减持及获利回吐一度回调5.11%，今日重新走强。此外，公司近期公告联合高瓴祈睿等合计向子公司凯莱英BIO增资12.4亿元，用于大分子CDMO产能建设，投后估值约42.4亿元，基本面支撑明确。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"凯莱英盘中上涨6.23%，CXO板块延续药明康德中报利好提振","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134705398","title":"异动解读｜凯莱英盘中下跌5.11%，多家机构近期持续减持叠加制药板块回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1134705398","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134705398?lang=zh_cn&edition=full","pubTime":"2026-08-06 13:31","pubTimestamp":1785994317,"startTime":"0","endTime":"0","summary":"8月6日，凯莱英盘中下跌5.11%，报107.8港元，成交额6568.77万港元。消息面上，近期多家机构持续减持凯莱英H股。Norges Bank于7月31日减持9.15万股，持股比例由6.05%降至5.72%；Schroders PLC于7月30日减持8.43万股，持股比例降至11.84%。此外，制药板块今日整体偏弱，恒瑞医药跌4.12%、石药集团跌0.36%、翰森制药跌0.64%。凯莱英此前于8月4日受药明康德中报提振大涨后，短期获利回吐压力有所显现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"凯莱英盘中下跌5.11%，多家机构近期持续减持叠加制药板块回调","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657752891","title":"凯莱英（002821）披露证券变动月报表，8月5日股价上涨1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657752891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657752891?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:06","pubTimestamp":1785938783,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，凯莱英报收于163.38元，较前一交易日上涨1.1%，最新总市值为589.44亿元。近日，凯莱英医药集团（天津）股份有限公司提交截至2026年7月31日的证券变动月报表。H股和A股的法定/注册股本均无变动，H股总数为27,834,510股，A股总数为332,946,460股，其中A股包含1,151,300股库存股。公司确认H股类别已符合联交所规定的公众持股量要求。现有股权激励计划项下，H股限制性股票计划下本月底可能发行或转让的股份为843,750股，其他协议无新增股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002821","BK1191","161027","LU1328615791.USD","BK0239","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115401461","title":"凯莱英7月股份变动月报：股本结构保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1115401461","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115401461?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:46","pubTimestamp":1785919595,"startTime":"0","endTime":"0","summary":"凯莱英医药集团（天津）股份有限公司于2026年8月5日发布截至2026年7月31日的证券变动月报表。根据公告，公司在报告期内未发生新增发行、股份回购或库存股变动，整体股本结构保持稳定。根据公告披露，截至2026年7月31日，公司普通股包括A股与H股。公司在公告中表示，截至2026年7月31日，H股公共持股比例符合香港联交所相关规定。截至报告期末，股本总数并未发生变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558706","title":"Norges Bank减持凯莱英(06821)9.15万股 每股作价约111.17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558706","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656558706?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:20","pubTimestamp":1785842406,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月31日，Norges Bank减持凯莱英(06821)9.15万股，每股作价111.171港元，总金额约为1017.21万港元。减持后最新持股数目为159.26万股，持股比例为5.72%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002821","ENOR","06821","BK0239","EWH","BK0132","BK1191","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.asymchem.com","stockEarnings":[{"period":"1week","weight":0.0981},{"period":"1month","weight":-0.0611},{"period":"3month","weight":0.2732},{"period":"6month","weight":0.4986},{"period":"1year","weight":0.2483},{"period":"ytd","weight":0.7059}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0441},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"凯莱英医药集团（天津）股份有限公司是一家主要从事提供医药外包一站式综合服务的中国公司。该公司的业务包括小分子药物定制研发生产（CDMO）、化学大分子CDMO、临床研究服务、制剂CDMO、生物大分子CDMO、技术输出和合成生物技术。该公司的产品类别涵盖多肽、寡核苷酸、单克隆抗体、抗体偶联药物和信使RNA等。该公司主要在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.058449},{"month":2,"riseRate":0.4,"avgChangeRate":0.006895},{"month":3,"riseRate":0.4,"avgChangeRate":0.004398},{"month":4,"riseRate":0.6,"avgChangeRate":-0.036171},{"month":5,"riseRate":0.4,"avgChangeRate":0.006805},{"month":6,"riseRate":0.6,"avgChangeRate":0.053806},{"month":7,"riseRate":0.6,"avgChangeRate":0.056483},{"month":8,"riseRate":0.4,"avgChangeRate":-0.036002},{"month":9,"riseRate":0.75,"avgChangeRate":0.163213},{"month":10,"riseRate":0,"avgChangeRate":-0.125552},{"month":11,"riseRate":0.5,"avgChangeRate":0.010601},{"month":12,"riseRate":0.25,"avgChangeRate":-0.010173}],"exchange":"SEHK","name":"凯莱英","nameEN":"ASYMCHEM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,06821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}